MVMD CEO Interview's on Agrarius™ technology and the opportunity for revolutionizing the agriculture industry
Soluvec 1%, which is 2,500 times more soluble than standard ivermectin, improves its potential efficacy and its ability to be absorbed as an antiparasitic in fish.
Mountain Valley MD Holdings Inc. has made significant progress in advancing the commercialization of its three core business areas
A Canadian biotech company that has applied its proprietary technology to the antiparasitic drug ivermectin to develop a more soluble medicine, Soluvec 1%
Canadian Bangladesh Agro Commences Soluvec Fish Feed Production
MVMD President & CEO, Dennis Hancock, discusses why it's important to prioritize sleep and how to set up the most effective routines.
Eons Launches Deeper Sleep Rapid Dissolve Mushroom Tablets powered by MVMD's proprietary Quicksome™ technology.
Heading into 2024, as with any annual flip of the calendar, we anticipate there will be topics of conversation that will fade away, persist, and develop — in the clinical trials industry as in life.
Sleepless in the City: How Mountain Valley MD is Pioneering Natural Sleep Solutions for a More Productive Workforce
MVMD to welcome new finance chief in January
Read the physical and pharmacokinetic characterization of MVMD's Soluvec™, a novel, solvent-free aqueous ivermectin formulation
Read about Agrarius™, the worlds first all-organic plant signaling technology
.jpg)
Read MVMD President & CEO, Dennis Hancock's, interview with Authority Magazine
Watch MVMD's 2022 Annual General Meeting recap video, reviewing all of MVMD's business lanes in depth
MVMD President & CEO, Dennis Hancock, comments on Agrarius technology and discusses current progress
MVMD starts commercial sales of Agrarius™, the newest innovation of organic plant signaling technology
Read the results for MVMD's Soluvec™ pre-clinical pharmacokinetic study.
MVMD showcases updates across the company's main lanes of business.
MVMD Announces the Acquisition of an Exclusive License for Agrarius and Launches a Performance Guarantee Program.
MVMD provides a broad business update across the three major lanes of business, nutraceuticals, agriculture, and animal husbandry.
.jpg)
“I am very pleased to welcome Yong Yao to the MVMD team to support our commercialization growth phase and the scaling of our operations globally,"
Announcement related to Transition of Chief Medical Officer To Advisory Role
Information about Mountain Valley MD Provides Notice...
Information about Mountain Valley MD Provides Business...
Information about Mountain Valley MD Commences Commercial...
Information about Mountain Valley MD Successfully Completes...
Information about Mountain Valley MD Holdings Provides...
Information about Mountain Valley MD Holdings Appoints...
Announcement related to Restricted Share Unit Plan, RSU Grant and Stock Option Grant
Information about Mountain Valley MD Holdings Completes...
Announcement related to Letter of Intent With Red White and Bloom Brands Inc.
Information about Mountain Valley MD Holdings Provides...
Announcement related to Voluntary Retraction of A Reported Data Set, No Material Change To Business Plan Anticipated
Announcement related to Annual Shareholder Meeting
Information about Mountain Valley MD Holdings To...
Information about Mountain Valley MD Appoints Chief...
Announcement related to Appointment of Advisors, Stock Option Grant, and Provides Uplisting Update
Announcement related to Results From Cold Chain Storage Evaluation Of Novel Quicksome™ Technology
Information about Mountain Valley MD Provides Update...
Information about Mountain Valley MD To Host...
Information about Mountain Valley MD Receives Successful...
Information about Mountain Valley MD Provides Update...
Information about Mountain Valley MD Proceeding with...
Information about Mountain Valley MD Holdings Inc....
Information about Mountain Valley MD Commencing Trials...
-singh-2989628.jpeg)
Achievement related to Solubilization of Selamectin, Files Trademark For Selactosol™
.jpeg)
Information about Mountain Valley MD Proceeding With...
Information about Mountain Valley MD Commencing Husbandry...
Information about Mountain Valley MD Confirms Quicksome™...
Information about Mountain Valley MD To Include...
Announcement related to Stock Option Grant and Warrant Exercise Update
Information about Mountain Valley MD Holdings To...
Information about Mountain Valley MD Contracts Tulane...
Information about Mountain Valley MD Proceeding with...
Information about Mountain Valley MD Files Patent...
Information about Mountain Valley MD Awarded Canadian...
Announcement related to Application for OTCQB Listing In U.S., Provides Update on Warrant Exercises
Information about Mountain Valley MD Completes Strategic...
Information about Mountain Valley MD Files For...
Information about Mountain Valley MD Holdings Oversubscribes...
Announcement related to Strategic Private Placement Offering of Units, Appointment of Advisor Board Members, and Proposed Debt Settlement
Information about Mountain Valley MD Confirms 800%...
Information about Mountain Valley MD Secures Quicksome™...
Information about Mountain Valley MD Files Patent...
Information about Mountain Valley MD Provides Successful...
Information about Leading Vaccine Expert Joins MVMD...
Information about Mountain Valley MD Secures Distribution...
Announcement related to Successful Complexation of Ivermectin Drug In Quicksome™ Oral Strip and Commencement of Pre-Clinical Trials
Information about U.S. Food And Drug Administration...
Information about Mountain Valley MD Holdings’ Subsidiary...
Information about Mountain Valley MD Holdings Inc....
Announcement related to New CFO, New Board Member, and Transition of Previous CFO To Advisory Role
Information about Mountain Valley MD Holdings Inc....
Information about Mountain Valley MD Holdings Inc....
Information about Mountain Valley MD Holdings Inc....
Over the past six months, MVMD has experienced transformative progress across our three main business lines, demonstrating the differentiation and positive reception of our technologies in the marketplace.
MVMD has acquired the exclusive license and distribution rights for the Agrarius™ technology across Canada and the USA, Mexico, South America, Central America, and the Caribbean. We will also retain our global non-exclusive rights outside of this exclusive territory.
MVMD President and CEO, Dennis Hancock, provides commercialization progress update.
It's been one year since I shared with our shareholders that MVMD was commencing our transition from an R&D-focused biotech start-up business into a commercially focused biotech entity.
Watch MVMD's 2023 AGM hosted on September 28th, 2023
MVMD executes license agreement, related studies, and patent expansion for Soluvec™
MVMD Welcomes Dr. Elizabeth Norton to Advisory Role / Cold Chain and Vaccine Progress
Register for MVMD AGM – Wednesday, September 29th
The addition of Gokul Kannan and Mark Gelnaw to the MVMD team is expected to bring significant value as we continue to advance our key oncology and technology initiatives.
MVMD Update: FDA, Oncology, Cold Chain, Husbandry and more
Mike Farber and Steve Darling from Proactive Investor discussed MVMD's new water-solubilized selamectin breakthrough
MVMD Files for a new, novel dose sparing patent for IPV Polio
The trial showcased that corn crops treated with Agrarius retained a 23% yield increase compared to the control group.
.jpg)
A grass-finished cattle company located in Placer County, California, tested Agrarius™ on fescue grass to evaluate its impact on cattle grazing land yields.
The Agrarius treatment led to a 20% increase in the overall yield of Napa cabbage, attributed to improved plant health and faster crop growth.
A sugarcane farm in Santa Cruz, Jamaica experienced a 20% yield increase when using Agrarius™ on their crops.
The use of Agrarius technology led to a significant boost in potato yields. The number of potatoes per plant increased from 14 to 30, and the overall weight of the yield increasing from 2.08kg to 3.78kg.
Stay plugged in on everything MVMD
Should you ever want to update your preferences or unsubscribe entirely, you can do so by contacting privacy@mvmd.com
